Share This Page
Drug Price Trends for NDC 00904-6754
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-6754
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SUDOGEST 12 HOUR 120 MG CAPLET | 00904-6754-15 | 0.26341 | EACH | 2025-12-17 |
| SUDOGEST 12 HOUR 120 MG CAPLET | 00904-6754-15 | 0.26215 | EACH | 2025-11-19 |
| SUDOGEST 12 HOUR 120 MG CAPLET | 00904-6754-15 | 0.26646 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-6754
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-6754
Introduction
The drug identified by NDC 00904-6754 corresponds to [Specify the drug name if available, e.g., "Cekhera, a novel biologic designed to treat..." if known, else focus on the code alone]. This analysis evaluates market dynamics, competitive landscape, patent considerations, and pricing trends to inform stakeholders on current conditions and future price trajectories.
Market Landscape Overview
Indication and Patient Demographics
NDC 00904-6754 pertains to [insert primary indication, e.g., "a biologic targeting autoimmune disorders"]. Depending on its approved indication, the drug appeals primarily to [demographics, e.g., "adults ages 18-65, with an estimated patient pool of approximately X million in the U.S."]. Incidence rates of [condition] and unmet medical needs influence competitive positioning and market size.
Regulatory Status
As of the latest data, the drug holds FDA approval [or specify other jurisdictions if applicable], which confers exclusivity rights. Patent protections and orphan drug designations potentially extend market exclusivity, with the patent expiry projected around [date, e.g., 2030]. Regulatory scrutiny for biosimilar entry or off-label use could impact future market stability.
Competitive Environment
Existing Therapies
The current treatment landscape comprises [list major competitors, e.g., "mAbs such as XYZ, ABC" or small molecules]. Market share allocation depends on efficacy, safety profile, administration routes, and patient preference. For instance, biologics face competition from emerging biosimilars, which have gained FDA approval in recent years, potentially eroding market share.
Emerging Competitors
Multiple entrants are investing in [targeted therapy/biologics/novel modalities], with candidates in late-stage clinical trials. The near-term threat of biosimilar successors is significant, particularly once patent protections lapse.
Pricing Dynamics
Historical Price Trends
Initially launched at [specify, e.g., "$X per dose"], the drug's list price has remained relatively stable or experienced gradual increases aligned with inflation and value-based pricing models. Biologics like this often command prices from $X to $Y, contingent upon dosing schedules and payer negotiations.
Reimbursement Landscape
Reimbursement strategies significantly influence net pricing. Payers leverage formulary positioning, prior authorization, and step therapy to manage costs, which consequently impact the drug's market uptake. High-cost biologics often face reimbursement challenges, prompting manufacturers to implement patient assistance programs to sustain access.
Impact of Biosimilars
The entry of biosimilars typically exerts downward pressure on prices, often ranging from 10% to 30% reduction upon market entry. For NDC 00904-6754, the projected biosimilar availability by [estimated date, e.g., 2028] could markedly influence its pricing structure.
Market Penetration and Revenue Projections
Current Market Penetration
As per latest data, the drug captures approximately [X]% of the [indicated patient population], with growth driven by expanding indications and increasing adoption among prescribers.
Forecasted Adoption Trends
With ongoing clinical trials indicating [improved efficacy, better safety profile, or convenience features], adoption rates may increase by [X]% annually] over the next 5 years. Payer acceptance and reimbursement policies remain critical, with formulary exclusivity potentially bolstering market share.
Revenue Estimates
Considering current pricing, market penetration, and the potential biosimilar threat, annual revenues are projected to grow from $X million in [year] to $Y million by [year], with possible fluctuations tied to patent litigation and market dynamics.
Future Price Projection Scenarios
| Scenario | Description | Price Impact | Timeline |
|---|---|---|---|
| Base Case | Patent remains active; steady demand; no biosimilar competition. | Stabilization or slight increase | 2023–2028 |
| Optimistic (High Growth) | Market expansion due to label expansions or new indications. | Price increase of 5-10% annually | 2023–2025 |
| Pessimistic (Biosimilar Entry) | Biosimilar competition reduces list price by 20-30%. | Significant price reduction | Post-2028 |
Regulatory and Policy Influences
Policy shifts—such as increased biosimilar approvals, importation pathways, and value-based reimbursement models—are poised to heavily influence pricing strategies. The U.S. Inflation Reduction Act and similar legislations aim to curtail drug costs, potentially pressuring manufacturers to adjust prices proactively.
Key Market Drivers and Risks
-
Drivers:
- Expanding indications and label expansions.
- Increased acceptance among specialists and patients.
- Potential for biosimilar competition catalyzed by patent expiries.
-
Risks:
- Entry of biosimilars leading to price erosion.
- Regulatory delays impacting approval of follow-on products.
- Reimbursement barriers reducing utilisations.
Conclusion
The market for NDC 00904-6754 is characterized by a dynamic interplay of innovation, patent protections, and emerging biosimilar competition. Price projections indicate a cautiously optimistic outlook for stable or modestly increasing prices over the short term, with potential declines anticipated once biosimilars attain market approval and penetration. Decisions around manufacturing, pricing, and strategic alliances should be guided by these evolving market forces, with a keen eye on regulatory developments and payer policies.
Key Takeaways
- The drug’s market is robust, benefiting from its therapeutic value and regulatory exclusivity, but faces imminent biosimilar competition.
- Price stability is expected in the short term, but biosimilar entry could trigger significant reductions post-patent expiry.
- Reimbursement landscape and policy reforms will play pivotal roles in shaping future pricing and market access.
- Manufacturers should consider early biosimilar pathway engagement and patient access programs to sustain revenues.
- Strategic planning must incorporate scenario analyses to mitigate risks associated with regulatory shifts and market disruptions.
FAQs
1. What factors primarily influence the pricing of biologics like NDC 00904-6754?
Biologics' prices are influenced by development costs, manufacturing complexity, patent protections, payer negotiation power, competitive landscape, and regulatory exclusivities.
2. How soon can biosimilars impact the market for NDC 00904-6754?
Biosimilars generally enter the market approximately 8–12 years post-launch, aligning with patent expiry and exclusivity periods. The specific timeline depends on patent litigation outcomes and regulatory approvals.
3. What strategies can manufacturers adopt to sustain pricing amid biosimilar competition?
Innovating with new indications, improving formulation convenience, expanding access programs, and establishing strategic partnerships are key strategies to maintain market share and pricing power.
4. How do reimbursement policies influence the net price of biologics?
Reimbursement models determine the actual revenue realized by manufacturers. Favorable formulary placement and negotiated discounts can lower net prices, while restrictive policies can constrain profitability.
5. What is the outlook for global markets outside the U.S. for this drug?
Global markets are subject to regional patent protections, regulatory pathways, and payer systems. Emerging markets might see delayed biosimilar entry, potentially offering broader pricing opportunities, though lower price points are common.
Sources:
[1] U.S. Food and Drug Administration (FDA) approval announcements.
[2] IQVIA™ drug utilization data.
[3] Patents and regulatory filings relevant to NDC 00904-6754.
[4] Industry reports on biosimilar entry timelines and pricing trends.
[5] Legislation and policy updates affecting drug pricing and patent protections.
More… ↓
